Evidence map›Paper›PMID 24228846›Full record

SynthesisMalaria journal2013

Spatial distribution of G6PD deficiency variants across malaria-endemic regions.

Rosalind E Howes, Mewahyu Dewi, Frédéric B Piel, Wuelton M Monteiro, Katherine E Battle, Jane P Messina, Anavaj Sakuntabhai, Ari W Satyagraha, Thomas N Williams, J Kevin Baird and 1 more

2 registry-linked trialsOpen access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Malaria journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 107 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 6 pooled it
21.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04416945 nawithdrawnnot on this mapstarted 2020, after this paper: background citation

Targeting High-risk Populations With Enhanced Reactive Case Detection: a Study to Assess the Effectiveness and Feasibility for Reducing Plasmodium Falciparum and P. Vivax Malaria in Southern Lao Peoples Democratic Republic

TypeinterventionalSponsorUniversity of California, San FranciscoRan2020 to 2021Enrolled0ConditionsPlasmodium Falciparum Malaria, Plasmodium Vivax MalariaArmsHousehold Reactive Case Detection, RACD of cases' co-workers/co-travelers, Case Management and Follow-up
NCT05052502 nacompletednot on this mapstarted 2020, after this paper: background citation

Targeting High-risk Populations With Enhanced Reactive Focal Mass Drug Administration: A Study to Assess the Effectiveness and Feasibility for Plasmodium Falciparum and Plasmodium Vivax Malaria in Thailand

TypeinterventionalSponsorUniversity of California, San FranciscoRan2020 to 2022Enrolled14,977ConditionsPlasmodium Falciparum Malaria, Plasmodium Vivax MalariaArmsCase Management and Follow-up, Reactive focal mass drug administration (rfMDA)
3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 6 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Tafenoquine: a toxicity overview.Expert opinion on drug safety · 2021
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Human genetic variations conferring resistance to malaria.Journal of translational medicine · 2025
    Review
  9. Radical Cure of Plasmodium vivax With Primaquine and CYP2D6 Polymorphism in Southeast Asia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  10. Article
  11. Associations between COVID-19 and Glucose-6-Phosphate Dehydrogenase Activity in Brazil.The American journal of tropical medicine and hygiene · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 5 countries.

Rosalind E HowesSpatial Ecology and Epidemiology Group, Department of Zoology, University of Oxford, South Parks Road, Oxford, UK. rosalind.howes@zoo.ox.ac.uk.
Mewahyu Dewi
Frédéric B Piel
Wuelton M Monteiro
Katherine E Battle
Jane P Messina
Anavaj Sakuntabhai
Ari W Satyagraha
Thomas N Williams
J Kevin Baird
Simon I Hay
University of Oxford · GBEijkman Institute for Molecular Biology · IDFundação de Medicina Tropical · BRInstitut Pasteur · FRKenya Medical Research Institute · KENuffield Orthopaedic Centre · GB

Funding

Wellcome Trust #085406Wellcome Trust #091758Wellcome Trust 091758Wellcome Trust 092654Wellcome Trust 095066Wellcome Trust #B9RJIXO
6 · The paper itself

Abstract

backgroundPrimaquine is essential for malaria control and elimination since it is the only available drug preventing multiple clinical attacks by relapses of Plasmodium vivax. It is also the only therapy against the sexual stages of Plasmodium falciparum infectious to mosquitoes, and is thus useful in preventing malaria transmission. However, the difficulties of diagnosing glucose-6-phosphate dehydrogenase deficiency (G6PDd) greatly hinder primaquine's widespread use, as this common genetic disorder makes patients susceptible to potentially severe and fatal primaquine-induced haemolysis. The risk of such an outcome varies widely among G6PD gene variants.

methodsA literature review was conducted to identify surveys of G6PD variant frequencies among representative population groups. Informative surveys were assembled into two map series: (1) those showing the relative proportions of the different variants among G6PDd individuals; and (2) those showing allele frequencies of G6PD variants based on population surveys without prior G6PDd screening.

resultsVariants showed conspicuous geographic patterns. A limited repertoire of variants was tested for across sub-Saharan Africa, which nevertheless indicated low genetic heterogeneity predominated by the G6PD A(-202A) mutation, though other mutations were common in western Africa. The severe G6PD Mediterranean variant was widespread across western Asia. Further east, a sharp shift in variants was identified, with high variant heterogeneity in the populations of China and the Asia-Pacific where no single variant dominated.

conclusionsG6PD variants exhibited distinctive region-specific distributions with important primaquine policy implications. Relative homogeneity in the Americas, Africa, and western Asia contrasted sharply with the heterogeneity of variants in China, Southeast Asia and Oceania. These findings will inform rational risk assessments for primaquine in developing public health strategies for malaria control and elimination, and support the future development of regionally targeted policies. The major knowledge gaps highlighted here strongly advocate for further investigation of G6PD variant diversity and their primaquine-sensitivity phenotypes.

Indexed as

Topography, MedicalAntimalarialsGene FrequencyGenetic VariationGlobal HealthGlucosephosphate Dehydrogenase DeficiencyHumansMalaria, FalciparumMalaria, VivaxPrimaquineRisk AssessmentSpatial AnalysisAntimalarialsPrimaquine

Identifiers

PMID24228846
PMCPMC3835423
OpenAlexW2082525341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.